Nippon Sanso Holdings Corporation (NSHD), through its European subsidiary Oximesa, has acquired Esteve Teijin Healthcare (ETH), in a move that reinforces its leadership in the home respiratory therapy sector in Spain.
Esteve Teijin Healthcare, a company specialising in home respiratory therapies founded in 2009, shares Oximesa’s philosophy, which is focused on delivering high-quality care and innovative services. This alliance will allow both companies to combine their extensive experience and expertise to provide even more effective, close, and humanised home care.
In Spain, NSHD provides respiratory therapy services through Oximesa. This new addition strengthens its commitment to continuous improvement, sustainable growth and, above all, to comprehensive and personalised care for every patient.
Justin Corcho, NSHD’s top representative in Spain and Portugal, highlighted, “The acquisition of Esteve Teijin Healthcare reaffirms our commitment, as well as NSHD’s, to the medical sector in Spain. The commitment we have made in Spain to our patients, alongside excellence in care and innovation in home respiratory therapies, has been fundamental in attracting a significant portion of the group’s investments to the Iberian Peninsula. This union consolidates our leadership and positions us at the forefront of the HRT sector, enabling us to successfully face future challenges, centred on quality, innovation and exceptional care for patients, collaborators and clients.”
Jorge Huertas, General Manager of Oximesa, stated: “The union of both companies is historic in the field of Home Respiratory Therapies. This opportunity will allow us to develop our company’s potential and vision. The entire Oximesa team is truly excited, since the acquisition will enhance the talent and capabilities of both organisations, reinforcing our commitment to providing professional and innovative care. Oximesa has demonstrated a firm dedication to improving both the quality of life and the experience of respiratory patients with a pioneering and human approach. We are convinced that Oximesa is the ideal environment for ETH professionals to continue their work with the utmost security, integrity and professionalism.”
Esteve Teijin Healthcare agrees that this operation consolidates the new brand as a benchmark in the Spanish market for home respiratory therapies, ensuring the continuity of ETH’s innovative approach and its long-term sustainability.
Carlos Fina, CEO of Esteve Teijin Healthcare, remarked: “We are convinced that this acquisition represents a great step forward for our company. It will bring new technical and human resources and will allow us to evolve towards an even more personalised, proactive and preventive model of care. The combination of our experience, professionalism and deep sector knowledge, together with Oximesa, will enable us to offer more effective and innovative solutions in the home care of respiratory patients.”
About Esteve Teijin Healthcare
Esteve Teijin Healthcare (ETH), a joint venture between Teijin and Corporación Químico Farmacéutica Esteve (50%-50% shareholding), is a company expert in home respiratory therapies, guaranteeing continuous patient care from hospital to home.
ETH has nearly 50 Respiratory Care Centres (CRETA), multiple integrated clinics within health centres, and 8 logistics centres. It currently employs more than 300 staff and serves over 190,000 respiratory patients throughout Spain.
Its mission is to improve health outcomes and wellbeing, promoting adherence to treatment and ensuring high quality standards. ETH is firmly committed to innovative and sustainable solutions that transform home care.
ETH Press Contact, Marta Canal – Communications Manager 📞 +34 679 854 041
About OXIMESA
Oximesa, a subsidiary of Nippon Sanso Holdings Corporation, is a leading company in home respiratory therapies with over 50 years’ experience in caring for patients with respiratory diseases. Its care model blends innovation, human care and patient safety, integrating technologies such as telemonitoring and remote care to provide proactive and personalised follow-up.
It has a strong infrastructure network throughout Spain, which includes medicinal oxygen manufacturing and filling centres, AEMPS-authorised warehouses, specialised technical services, mobile units and Patient Care Centres (CentrOX). All this is backed by a highly qualified team committed to care excellence. More than 370,000 patients currently benefit from its services, reflecting the company’s purpose: to make quality of life a reality for people with respiratory diseases.
OXIMESA Press Contact, David García Prieto – Communications Manager 📞 +34 699 066 55